Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Enlivex Therapeutics Ltd
ENLV | US
0.84
USD-0.12
-12.82%
ENLV | US
Loading StockChartView...
About Enlivex Therapeutics Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
0.84
Open
0.87
High
0.91
Low
0.74
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona Israel.
View LessENLV | US
Risk
110.8
Sharpe
-0.17
Luna's Score
37/100
Recommendation
Sell
Luna says (ENLV | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
128.8%1 month
110.8%3 months
86.0%6 months
80.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.22
Debt to equity
0.03
Debt to assets
0.03
Ent. to EBITDA
-1.49
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-17.89M
MarketCap
17.94M
MarketCap(USD)
17.94M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-61.17
Short ratio
0.70
Short perc.
0.52
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.32
Range1M
0.58
Range3M
0.58
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.77
Price X volume
1.53M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.49 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.22 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 86.01 | 72.80 | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 17.94M | 3.66B | Emerging |
